The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 358:433-434 January 24, 2008 Number 4
NextNext

The Normal Hematocrit Study — Follow-up

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: We previously reported in the Journal the results of a randomized, prospective study comparing outcomes of normal versus low hematocrit values in 1233 patients with congestive heart failure or ischemic heart disease who were undergoing hemodialysis and receiving treatment with epoetin alfa; 618 patients were randomly assigned to the normal-hematocrit group, and 615 to the low-hematocrit group.1 The primary end point was the length of time to death or a first nonfatal myocardial infarction. The editors of the Journal requested that we now provide supplemental data, including end-point events that occurred after the data set was analyzed . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.